Abstract
Background and Objectives: Panel-reactive antibody (PRA) negativity is commonly used to classify kidney transplant recipients as low immunological risk and to select less intensive induction. We compared early biopsy-proven rejection (BPR) among PRA-negative living-donor recipients before and after an institutional change from basiliximab to rabbit anti-thymocyte globulin (rATG) induction. Materials and Methods: Single-center retrospective cohort of adult PRA-negative living-donor recipients transplanted between October 2020 and October 2025 and followed to 31 August 2026. Induction was assigned by protocol era (basiliximab before, rATG after February 2025), so agent and era were inseparable. Propensity-score matching was performed on 11 pre-transplant covariates. All biopsies were for cause. The era comparison was defined post hoc. Results: Of 286 recipients, 147 basiliximab and 81 rATG recipients were matched. Biopsy was performed in 10.9% and 1.2%, respectively. BPR occurred in 13/147 (8.8%) and 0/81 recipients (risk difference −8.8 percentage points, 95% CI −14.9 to −2.0), all by post-operative day 10. In a tipping-point analysis, a single undetected rATG event removed statistical significance on the match-weighted comparison. Median follow-up was 1478 versus 408 days. The observed incidence rate of any BK viremia was higher in the rATG era (14.3 vs. 2.7 per 100 patient-years), although unequal follow-up limits interpretation. Conclusions: Early BPR occurred in nearly one in eleven PRA-negative living-donor recipients given basiliximab. The rATG era was associated with fewer recorded early rejections, but this association is confounded by calendar era, sensitive to differential biopsy ascertainment and accompanied by a higher observed BK viremia incidence rate over unequal follow-up. These data do not support a change in induction practice; they motivate a prospective comparison with uniform biopsy policy and HLA-mismatch data.